Search Results
Jul 27, 2026, 22:35 ET Akeso IO2.0 + ADC2.0 Strategy Makes Another Advancement: First Patient Dosed in Phase Ib/II Study of HER3 ADC (AK138D1) Combined with Ivonescimab in Lung Cancer
upgrades for major malignancies, including lung cancer and breast cancer.About AK138D1Injectable AK138D1 is a HER3-targeted antibody-drug conjugate (ADC), with a fully humanized anti-HER3 IgG1 antibody, patritumab. It is conjugated to the topoisomerase I inhibitor DXd through a cleavable
More news about: Akeso, Inc.
Jul 27, 2026, 19:23 ET Erasca, Inc. Deadline: ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit
its lead oncology drug candidate, ERAS-0015, throughout the Class Period. According to the complaint, Erasca repeatedly touted ERAS-0015 as a potential "best-in-class" therapy and highlighted purportedly superior preclinical results compared to Revolution Medicines' competing drug candidate, RMC-6236,
More news about: THE ROSEN LAW FIRM, P. A.
Jul 27, 2026, 15:58 ET Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
action.What is this about: On February 13, 2026, the U.S. Food and Drug Administration ("FDA") issued a Complete Response Letter ("CRL") to Disc Medicine regarding its bitopertin program. The FDA stated they could not approve Disc Medicine's new drug application ("NDA") as there were uncertainties in the NDA
More news about: THE ROSEN LAW FIRM, P. A.
Jul 27, 2026, 13:48 ET Liberty HealthShare Earns Another Candid Gold Seal, Reinforcing Commitment to Transparency and Stewardship
individuals and start at $319 for families. Most programs include sharing eligibility for urgent care and mental wellness telehealth visits along prescription drug discounts.As a healthcare sharing ministry and not insurance, Liberty HealthShare offers year-round enrollment without requiring a qualifying
More news about: Liberty HealthShare
Jul 27, 2026, 10:31 ET Food Allergy Market on the Rise: 5 Emerging Therapies to Watch | DelveInsight
improving convenience, addressing needle anxiety, and reducing the burden associated with carrying injectable devices.Discover industry-sponsored drug assets for food allergy development phases @
More news about: DelveInsight Business Research, LLP
Jul 27, 2026, 10:00 ET The Speak Foundation Announces 2026 LGMD Scientific Summit
Cure Rare Disease.PATIENT-CENTERED DRUG DEVELOPMENTA featured panel will bring together representatives from the U.S. Food and Drug Administration and the patient community to examine patient-centered clinical trial design, stakeholder
More news about: The Speak Foundation
Jul 27, 2026, 09:12 ET DifGen Pharmaceuticals Receives FDA Clearance to Begin Clinical Development for a Single Injection treatment for Advanced Breast Cancer DFGN-101
require a clinical endpoint efficacy study. DifGen Pharmaceuticals LLC today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Investigational New Drug (IND) application and issued a "study may proceed" letter for DFGN-101, an intramuscular injection under development
More news about: DifGen Pharmaceuticals LLC
Jul 27, 2026, 09:05 ET AbelZeta Receives FDA Clearance of Registrational Phase II Trial for C-CAR168 in Refractory Lupus Nephritis
discovery and development of innovative and proprietary cell-based therapeutic products, today announced that the Company received the U.S. Food and Drug Administration (FDA) clearance under its Regenerative Medicine Advanced Therapy (RMAT) designation regarding the multiple-center registrational Phase
More news about: AbelZeta Pharma, Inc.
Jul 27, 2026, 09:05 ET BioMarin and n-Lorem Foundation Enter Early Research Collaboration to Develop Potential First-in-Disease Medicine for Newly Identified ReNU Syndrome
a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound
More news about: BioMarin Pharmaceutical Inc.
Jul 27, 2026, 09:00 ET Decoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire, Expanding D-MAV™ Platform into High Consequence Global Health Threats
Ebola outbreaks, demonstrates the value of the platform's founding premise that one drug engineered against common viral machinery can address many viruses and serve many people."Viruses don't operate in a one-drug, one-virus silo, and our industry's legacy reactive model has left the world playing
More news about: Decoy Therapeutics, Inc
Jul 27, 2026, 09:00 ET AsymBio Kicks Off Construction of Fengxian R&D Building to Establish a Full-Lifecycle, One-Stop Biologics Service Ecosystem
conjugation process development, drug product development, and comprehensive analytical development services.Located within AsymBio's Fengxian site, adjacent to the clinical and commercial manufacturing facilities for antibodies and antibody-drug conjugates (ADCs), the building will
More news about: AsymBio
Jul 27, 2026, 09:00 ET Mana.bio Announces the Appointment of Laura Sepp-Lorenzino to its Scientific Advisory Board
hepatic infectious disease programs and served as Entrepreneur-in-Residence. She began her industrial career at Merck & Co., leading RNAi and oncology drug discovery efforts.Dr. Sepp-Lorenzino currently serves on the board of directors of Taysha Gene Therapies, Asklepios Biopharmaceutical (AskBio),
More news about: Mana.bio
Jul 27, 2026, 09:00 ET The AI Buildout Has a Power Problem, and the Grid Is Not Going to Solve It in Time
into an environment that companies of Vertiv's size are actively redesigning.Until July 2, this was LIXTE Biotechnology Holdings, an oncology drug developer trading under the ticker LIXT. It completed a merger with NOMAD Transportable Power Systems, changed its name, and began trading as NMAD on
More news about: USA News Group
Jul 27, 2026, 08:56 ET Pictor Debuts New PictImager® at ADLM 2026 to Make Targeted Protein Analysis More Practical
full commercial launch later this year.Targeted protein analysis is gaining momentum across translational research, biomarker discovery, and drug development. Adoption, however, remains constrained by workflow, specialized instrumentation, cost, and complexity. Pictor's platform is designed to
More news about: Pictor Holdings Inc.
Jul 27, 2026, 08:56 ET Pictor Debuts New PictImager® at ADLM 2026 to Make Targeted Protein Analysis More Practical
full commercial launch later this year.Targeted protein analysis is gaining momentum across translational research, biomarker discovery, and drug development. Adoption, however, remains constrained by workflow, specialized instrumentation, cost, and complexity. Pictor's platform is designed to
More news about: Pictor Holdings Inc.
Jul 27, 2026, 08:32 ET IceCure Medical Kicks Off its Post-Marketing "ChoICE" Study for the Low-Risk Breast Cancer Treatment at First U.S Clinical Site
ChoICE," (the "ChoICE Study"), for ProSense® in the treatment of low-risk breast cancer following U.S Food and Drug Administration ("FDA") marketing authorization in October 2025. The ChoICE Study will enroll up to 400 patients across 30 U.S. sites, gathering real-world
More news about: IceCure Medical
Jul 27, 2026, 08:15 ET ViaPath Technologies Intelligence Services Supports ODRC Investigations Disrupting Drone-Assisted Contraband Operation
intelligence analyst worked closely with corrections and law enforcement partners to identify and disrupt a coordinated operation involving drone-assisted drug trafficking. Through ongoing monitoring, investigative analysis, and real-time coordination with law enforcement, the analyst helped identify a network
More news about: ViaPath Technologies
Jul 27, 2026, 08:10 ET Waters Launches Industry's Most Sensitive and Robust Clinical IVD System with Xevo TQ Absolute XR IVD Mass Spectrometer
Application Note: Extraction and Analysis of a Definitive Drug Panel in Hair Samples by UHPLC-MS/MS for Forensic ToxicologyXevo, StepWave, MassTrak, ACQUITY, and Waters are trademarks of Waters Corporation
More news about: Waters Corporation
Jul 27, 2026, 08:10 ET Waters Launches Industry's Most Sensitive and Robust Clinical IVD System with Xevo TQ Absolute XR IVD Mass Spectrometer
Application Note: Extraction and Analysis of a Definitive Drug Panel in Hair Samples by UHPLC-MS/MS for Forensic Toxicology Xevo, StepWave, MassTrak, ACQUITY, and Waters are trademarks of Waters
More news about: Waters Corporation
Jul 27, 2026, 08:01 ET SHARx Says Pharmacy Benefits Have Become a Major Spend Category With No Clear Owner
al Trade Commission. (2024, July 9). FTC releases interim staff report on prescription drug middlemen. ftc.gov/news-events/news/press-releases/2024/07/ftc-releases-interim-staff-report-prescription-drug-middlemenGupta, A., & Knott, D. (2025, June 26). Transforming employer health
More news about: SHARx
Jul 27, 2026, 08:00 ET Insilico Medicine Announces Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of ISM6331 in Mesothelioma and Advanced Solid Tumors
July 27, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", HKEX:3696), a clinical-stage, generative AI-driven drug discovery company, today announced that first-in-human Phase 1 trial data for ISM6331, its novel AI-designed pan-TEAD inhibitor, has been accepted for
More news about: Insilico Medicine
Jul 27, 2026, 08:00 ET Valeris Restores Full Copay Assistance Value for Client Brands After SaveOn SP Copay Maximizer Removal
commercialization partner, announced today that several brands under its patient affordability management have been removed from the SaveOn SP copay maximizer drug list, marking a significant win for manufacturer partners and the patients who depend on their therapies.
More news about: Valeris
Jul 27, 2026, 08:00 ET Labcorp Launches Marker by Labcorp™ Genetic Health Panel, Expanding Consumer Access to Hereditary Genetic Risk Testing
clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than
More news about: Labcorp
Jul 27, 2026, 07:30 ET Kelun-Biotech Receives a Clinical Trial Notice for Its First Dual-payload ADC SKB565
received a clinical trial notice from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) approving the Investigational New Drug (IND) application for its novel dual-payload ADC drug, SKB565, for the treatment of advanced solid
More news about: Kelun-Biotech
Jul 27, 2026, 07:00 ET Federal Jury Finds Avilar Therapeutics and RA Capital Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Awards Biohaven and Yale University $4 Million
Avilar Therapeutics, a company RA Capital helped establish later that year, used confidential information from those discussions to build a competing drug development program instead of pursuing a partnership with Yale.Biohaven licensed the MODA platform from Yale to develop and commercialize
More news about: Biohaven Ltd.